☰

Nicolas Lindegger, PhD - Publications

Affiliations: 
Novartis, Basel, Basel-Stadt, France 
Tree Info Grants Similar researchers PubMed Report error

5/188 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2009 Lindegger N, Hagen BM, Marks AR, Lederer WJ, Kass RS. Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. Journal of Molecular and Cellular Cardiology. 47: 326-34. PMID 19371746 DOI: 10.1016/J.Yjmcc.2009.04.003  0.505
2008 Kass RS, Lindegger N, Hagen B, Lederer WJ. Another calcium paradox in heart failure. Journal of Molecular and Cellular Cardiology. 45: 28-31. PMID 18504047 DOI: 10.1016/j.yjmcc.2008.04.001  0.344
2008 Lehnart SE, Mongillo M, Bellinger A, Lindegger N, Chen BX, Hsueh W, Reiken S, Wronska A, Drew LJ, Ward CW, Lederer WJ, Kass RS, Morley G, Marks AR. Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. The Journal of Clinical Investigation. 118: 2230-45. PMID 18483626 DOI: 10.1172/Jci35346  0.402
2006 Momotake A, Lindegger N, Niggli E, Barsotti RJ, Ellis-Davies GC. The nitrodibenzofuran chromophore: a new caging group for ultra-efficient photolysis in living cells. Nature Methods. 3: 35-40. PMID 16369551 DOI: 10.1038/Nmeth821  0.514
2005 Lindegger N, Niggli E. Paradoxical SR Ca2+ release in guinea-pig cardiac myocytes after beta-adrenergic stimulation revealed by two-photon photolysis of caged Ca2+. The Journal of Physiology. 565: 801-13. PMID 15774509 DOI: 10.1113/Jphysiol.2005.084376  0.526
Low-probability matches (unlikely to be authored by this person)
2010 Shan J, Kushnir A, Betzenhauser MJ, Reiken S, Li J, Lehnart SE, Lindegger N, Mongillo M, Mohler PJ, Marks AR. Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. The Journal of Clinical Investigation. 120: 4388-98. PMID 21099118 DOI: 10.1172/Jci32726  0.3
2006 Fredj S, Lindegger N, Sampson KJ, Carmeliet P, Kass RS. Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes. Circulation Research. 99: 1225-32. PMID 17082480 DOI: 10.1161/01.Res.0000251305.25604.B0  0.18
2019 Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. European Journal of Cancer (Oxford, England : 1990). 109: 92-102. PMID 30708264 DOI: 10.1016/j.ejca.2018.12.022  0.175
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2018 Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Zambetti M, Woodward N, Ten Tije A, Lindegger N, Crespel G, Truman M, Steger G. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program European Journal of Cancer. 92: S105-S106. DOI: 10.1016/s0959-8049(18)30542-2  0.162
2019 Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30796821 DOI: 10.1093/annonc/mdz061  0.159
2019 Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30796821 DOI: 10.1093/annonc/mdz061  0.159
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2018 Steger G, Puglisi F, Timcheva C, Costa L, Casa-Nova M, Hitzl D, Dampier B, Lindegger N. SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC) Annals of Oncology. 29: viii119. DOI: 10.1093/annonc/mdy272.353  0.151
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2017 Barrios CH, Wuerstlein R, Anton A, Delaloge S, Montemurro F, Bonneterre J, Quenel-Tueux N, Linn SC, Button P, Lindegger N, Ellis PA. Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1. Journal of Clinical Oncology. 35: 1033-1033. DOI: 10.1200/JCO.2017.35.15_suppl.1033  0.139
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2012 Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment Chest. 142: 826A. DOI: 10.1378/chest.1386270  0.136
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2019 Sanglier T, Fabi A, Flores C, Flahavan E, Lindegger N, Montemurro F. Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW) Annals of Oncology. 30: v129. DOI: 10.1093/annonc/mdz242.051  0.135
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2012 Sidharta P, Lindegger N, Ulč I, van Giersbergen P, Dingemanse J. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment Chest. 142: 830A. DOI: 10.1378/chest.1387371  0.133
2014 Lindegger N, Sidharta PN, Reseski K, Dingemanse J. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects. Pulmonary Pharmacology & Therapeutics. 29: 41-8. PMID 24813561 DOI: 10.1016/j.pupt.2014.04.007  0.126
2022 DeBusk K, Ike C, Lindegger N, Schwartz N, Surinach A, Liu Y, Forero-Torres A. Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases. Journal of Managed Care & Specialty Pharmacy. 28: 657-666. PMID 35621719 DOI: 10.18553/jmcp.2022.28.6.657  0.117
2014 Sidharta PN, Lindegger N, Ul? I, Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. Journal of Clinical Pharmacology. 54: 291-300. PMID 24122797 DOI: 10.1002/jcph.193  0.09
2008 Lindegger N, Mongillo M. Look beyond the hERG mutation: a neutral SCN5A variant may turn lidocaine into a threat. Heart Rhythm : the Official Journal of the Heart Rhythm Society. 5: 1575-6. PMID 18984535 DOI: 10.1016/j.hrthm.2008.09.006  0.047
2008 Lindegger N, Kass RS. K+ channelopathies (I Ks and i Kr) Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention. 194-206. DOI: 10.1007/978-1-84628-854-8_12  0.02
Hide low-probability matches.